Abstract
Visualisation of primary prostate cancer, its relapse and its metastases is a clinically relevant problem despite the availability of state-of-the-art methods such as CT, MRI, transrectal ultrasound and fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG PET). The aim of this study was to evaluate the efficacy of carbon-11 acetate and 18F-FDG PET in the detection of prostate cancer and its metastases. Twenty-five patients were investigated during the follow-up of primary prostate cancer, suspected relapse or metastatic disease using 11C-acetate PET; 15 of these patients were additionally investigated using 18F-FDG PET. Fourteen patients were receiving anti-androgen treatment at the time of the investigation. Lesions were detected in 20/24 (83%) patients using 11C-acetate PET and in 10/15 (75%) patients using 18F-FDG PET. Based on the results of both PET scans, one patient was diagnosed with recurrent lung cancer. Median 18F-FDG uptake exceeded that of 11C-acetate in distant metastases (SUV =3.2 vs 2.3). However, in local recurrence and in regional lymph node metastases, 11C-acetate uptake (median SUVs =2.9 and 3.8, respectively) was higher than that of 18F-FDG (median SUVs =1.0 and 1.1, respectively). A positive correlation was observed between serum PSA level and both 11C-acetate uptake and 18F-FDG uptake. 11C-acetate seems more useful than 18F-FDG in the detection of local recurrences and regional lymph node metastases. 18F-FDG, however, appears to be more accurate in visualising distant metastases. There may be a role for combined 11C-acetate/18F-FDG PET in the follow-up of patients with prostate cancer and persisting or increasing PSA.
This is a preview of subscription content, log in via an institution to check access.
References
Dennis LK, Resnick MI. Analysis of recent trends in prostate cancer incidence and mortality. Prostate 2000; 42:247–252.
Seltzer MA, Barbaric Z, Belldegrun A, Naitoh J, Dorey F, Phelps ME, Gambhir SS, Hoh CK. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 1999; 162:1322–1328.
Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999; 36:31–35.
Kotzerke J, Volkmer B, Neumaier B, Gschwend JE, Hautmann RE, Reske SN. Carbon-11-acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med 2002; 29:1380–1384.
Costello LC, Franklin RB. Citrate metabolism of normal and malignant prostate epithelial cells. Urology 1997; 50:3–12.
Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-d-glucose: variations with body weight and a method for correction. Radiology 1993; 189:847–850.
Meyer GJ, Günther K, Matzke KH, Harms T, Hundeshagen H. A modified preparation method for11C acetate, preventing liquid phase extraction steps. J Labelled Comp Radiopharm 1993; 32:182–183.
Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-d-glucose. Radiology 1996; 199:751–756.
Effert PJ, Bares R, Handt S, Wolff JM, Büll U, Jakse G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol 1996; 155:994–998.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fricke, E., Machtens, S., Hofmann, M. et al. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 30, 607–611 (2003). https://doi.org/10.1007/s00259-002-1104-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-002-1104-y